Brandes Alba A, Bartolotti Marco, Tosoni Alicia, Poggi Rosalba, Franceschi Enrico
Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy.
Oncologist. 2015 Feb;20(2):166-75. doi: 10.1634/theoncologist.2014-0330. Epub 2015 Jan 7.
Bevacizumab, currently an option for treatment of different types of tumors including glioblastoma, has a peculiar toxicity profile related to its antiangiogenic effect. Because some bevacizumab-related adverse events can be life threatening, it is important to identify risk factors and to establish treatment protocols to minimize treatment-related morbidity and mortality. In glioblastoma patients, the risk of developing certain side effects, such as gastrointestinal perforation, venous thromboembolism, and intracranial hemorrhages, is slightly higher than in patients treated with bevacizumab for other tumor types. We performed a systematic review of the side effects of bevacizumab and their incidence, causal mechanisms, and available treatments. Finally, we identified risk factors and proposed preventive and therapeutic measures for these adverse events.
贝伐单抗目前是包括胶质母细胞瘤在内的不同类型肿瘤的一种治疗选择，因其抗血管生成作用而具有独特的毒性特征。由于一些与贝伐单抗相关的不良事件可能危及生命，识别风险因素并制定治疗方案以尽量减少治疗相关的发病率和死亡率非常重要。在胶质母细胞瘤患者中，发生某些副作用（如胃肠道穿孔、静脉血栓栓塞和颅内出血）的风险略高于接受贝伐单抗治疗的其他肿瘤类型患者。我们对贝伐单抗的副作用及其发生率、因果机制和可用治疗方法进行了系统综述。最后，我们确定了风险因素，并针对这些不良事件提出了预防和治疗措施。
